MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|5|1|3-8

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.1, 2005-02, pp. : 3-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics

By  

Mini Reviews in Medicinal Chemistry, Vol. 3, Iss. 3, 2003-05 ,pp. : 257-270

Bentham Science Publishers

Access to resources Recommend Favorite

P53 Mdm2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 18, Iss. 30, 2012-10 ,pp. : 4668-4678

Bentham Science Publishers

Access to resources Recommend Favorite

Small Molecule Inhibitors of the p53-MDM2

By  

Current Medicinal Chemistry, Vol. 15, Iss. 17, 2008-07 ,pp. : 1720-1730

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

By  

Current Medicinal Chemistry, Vol. 21, Iss. 5, 2014-02 ,pp. : 553-574

Bentham Science Publishers

Access to resources Recommend Favorite

Patented small molecule inhibitors of p53–MDM2 interaction

By Deng Jinxia   Dayam Raveendra   Neamati Nouri  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 2, 2006-02 ,pp. : 165-188

Informa Healthcare

Access to resources Recommend Favorite